Regencell Bioscience (NASDAQ:RGC) Shares Gap Down – Here’s What Happened

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s share price gapped down prior to trading on Monday . The stock had previously closed at $23.35, but opened at $21.60. Regencell Bioscience shares last traded at $21.33, with a volume of 45,564 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Regencell Bioscience Stock Performance

The stock has a 50-day simple moving average of $29.12 and a 200 day simple moving average of $20.41.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Squarepoint Ops LLC purchased a new position in shares of Regencell Bioscience during the 2nd quarter valued at approximately $1,701,000. Geode Capital Management LLC boosted its holdings in Regencell Bioscience by 5,637.5% during the second quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock worth $6,664,000 after buying an additional 384,250 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in Regencell Bioscience during the second quarter valued at $768,000. Vident Advisory LLC increased its holdings in Regencell Bioscience by 65.7% in the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after buying an additional 11,866 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Regencell Bioscience in the third quarter valued at $598,000. 0.13% of the stock is currently owned by hedge funds and other institutional investors.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.